Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0598766 (
leukemogenesis
)
4,065
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The monocytic leukemia zinc finger protein KAT6A (formerly MOZ) gene is recurrently rearranged by chromosomal translocations in acute myeloid leukemia (AML). KAT6A is known to be fused to several genes, all of which have histone acetyltransferase (HAT) activity and interact with a number of transcription factors as a transcriptional coactivator. The present study shows that the
leucine twenty homeobox
(
LEUTX
) gene on 19q13 is fused to the KAT6A gene on 8p11 in a therapy-related AML with t(8;19)(p11;q13) using the cDNA bubble PCR method. The fusion transcripts contained 83 nucleotides upstream of the first ATG of
LEUTX
and are presumed to create in-frame fusion proteins.
LEUTX
is known to have a homeobox domain. Expression of the
LEUTX
gene was only detected in placenta RNA by RT-PCR, but not in any tissues by Northern blot analysis. The putative
LEUTX
protein does not contain any HAT domain, and this is the first study to report that KAT6A can fuse to the homeobox gene. The current study, with identification of a new partner gene to KAT6A in a therapy-related AML, does not elucidate the mechanisms of
leukemogenesis
in KAT6A-related AML but describes a new gene with a different putative function.
...
PMID:The leucine twenty homeobox (LEUTX) gene, which lacks a histone acetyltransferase domain, is fused to KAT6A in therapy-related acute myeloid leukemia with t(8;19)(p11;q13). 2444 90